Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RevM10 or RevM10/polAS Transduced HSC in HIV-Related NHL
NCT00003942Phase 2Unknown
- Sponsor
- Systemix, Inc.
- Start
- Nov 1998
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of RevM10-transduced hematopoietic stem cells in non-Hodgkin lymphoma (NHL), sponsored by Systemix, Inc. Primary endpoint: Safety of infusion of RevM10 or RevM10/polAS transduced HSC at 1 year. Status: unknown.
02
Drugs
RevM10-transduced hematopoietic stem cells
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00003942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003942.